FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1425-1436 September 30, 2004 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Pulmonary arterial hypertension is a disease of the small pulmonary arteries that is characterized by vascular proliferation and remodeling.^1,2 It results in a progressive increase in pulmonary vascular resistance and, ultimately, right ventricular failure and death. A diagnosis of primary (or idiopathic) pulmonary hypertension is made when no known risk factor is identified.^3,4 The diagnostic classification of pulmonary arterial hypertension is described in Table 1.³ Despite recent major improvements in symptomatic treatments, no current treatment cures this devastating condition.^{1,2,5,6,7,8,9} However, during the past 20 years, treatment options for patients with the disease have evolved to help prolong their survival . . . [Full Text of this Article]

Pathophysiological Features

Natural History and Survival

Therapeutic Strategies

Basic Therapy

Calcium-Channel Blockers

Prostacyclin Therapy

Intravenous Prostacyclin

Subcutaneous Treprostinil

Oral Beraprost

Inhaled Iloprost

Endothelin-Receptor Antagonists

Bosentan

Sitaxsentan and Ambrisentan

Potential Future Therapies

Nitric Oxide

Sildenafil

Vasoactive Intestinal Peptide

Selective Serotonin-Reuptake Inhibitors

Combination Therapy

Treatment Algorithms

Source Information

From Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l'Enseignement Superieur EA2705, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique–Hôpitaux de Paris, Clamart, France.

Address reprint requests to Dr. Humbert at the Service de Pneumologie, Hôpital Antoine-Béclère, 157 Rue de la Porte de Trivaux, 92140 Clamart, France, or at marc.humbert@abc.aphp.fr.

Related Letters:

Treatment of Pulmonary Arterial Hypertension
Huisman A.-M., Vreugdenhil S. A., van Paassen H. C., Humbert M., Sitbon O., Simonneau G.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:308-309, Jan 20, 2005. Correspondence

This article has been cited by other articles:

• Humbert, M., Hoeper, M. M. (2008). Severe Pulmonary Arterial Hypertension: A Forme Fruste of Cancer?. Am. J. Respir. Crit. Care Med. 178: 551-552 [Full Text]  
• Stolz, D., Rasch, H., Linka, A., Di Valentino, M., Meyer, A., Brutsche, M., Tamm, M. (2008). A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32: 619-628 [Abstract] [Full Text]  
• Nickel, N., Kempf, T., Tapken, H., Tongers, J., Laenger, F., Lehmann, U., Golpon, H., Olsson, K., Wilkins, M. R., Gibbs, J. S. R., Hoeper, M. M., Wollert, K. C. (2008). Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 534-541 [Abstract] [Full Text]  
• Opitz, C. F., Ewert, R., Kirch, W., Pittrow, D. (2008). Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J 29: 1936-1948 [Abstract] [Full Text]  
• Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M. (2008). Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease 2: 249-265 [Abstract]  
• Provencher, S., Herve, P., Sitbon, O., Humbert, M., Simonneau, G., Chemla, D. (2008). Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 32: 393-398 [Abstract] [Full Text]  
• Suntharalingam, J., Treacy, C. M., Doughty, N. J., Goldsmith, K., Soon, E., Toshner, M. R., Sheares, K. K., Hughes, R., Morrell, N. W., Pepke-Zaba, J. (2008). Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest 134: 229-236 [Abstract] [Full Text]  
• Benza, R. L., Rayburn, B. K., Tallaj, J. A., Pamboukian, S. V., Bourge, R. C. (2008). Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension: Long-term Efficacy and Combination With Bosentan. Chest 134: 139-145 [Abstract] [Full Text]  
• Perros, F., Montani, D., Dorfmuller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., Herve, P., Emilie, D., Eddahibi, S., Simonneau, G., Souza, R., Humbert, M. (2008). Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 81-88 [Abstract] [Full Text]  
• Sztrymf, B., Coulet, F., Girerd, B., Yaici, A., Jais, X., Sitbon, O., Montani, D., Souza, R., Simonneau, G., Soubrier, F., Humbert, M. (2008). Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. Am. J. Respir. Crit. Care Med. 177: 1377-1383 [Abstract] [Full Text]  
• Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Gerber, M. J., Dufton, C., Wiens, B. L., Rubin, L. J., for the Ambrisentan in Pulmonary Arterial Hyperten, (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117: 3010-3019 [Abstract] [Full Text]  
• MacKnight, B., Martinez, E. A., Simon, B. A. (2008). Anesthetic Management of Patients With Pulmonary Hypertension. SEMIN CARDIOTHORAC VASC ANESTH 12: 91-96 [Abstract]  
• Syeda, F., Tullis, E., Slutsky, A. S., Zhang, H. (2008). Human neutrophil peptides upregulate expression of COX-2 and endothelin-1 by inducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 294: H2769-H2774 [Abstract] [Full Text]  
• Shah, S. J., Thenappan, T., Rich, S., Tian, L., Archer, S. L., Gomberg-Maitland, M. (2008). Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. Circulation 117: 2475-2483 [Abstract] [Full Text]  
• Humbert, M. (2008). Update in Pulmonary Arterial Hypertension 2007. Am. J. Respir. Crit. Care Med. 177: 574-579 [Full Text]  
• Souza, R., Humbert, M., Sztrymf, B., Jais, X., Yaici, A., Le Pavec, J., Parent, F., Herve, P., Soubrier, F., Sitbon, O., Simonneau, G. (2008). Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31: 343-348 [Abstract] [Full Text]  
• Petersen, B., Deja, M., Bartholdy, R., Donaubauer, B., Laudi, S., Francis, R. C. E., Boemke, W., Kaisers, U., Busch, T. (2008). Inhalation of the ETA receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R601-R605 [Abstract] [Full Text]  
• Ivy, D. D., Doran, A. K., Smith, K. J., Mallory, G. B. Jr, Beghetti, M., Barst, R. J., Brady, D., Law, Y., Parker, D., Claussen, L., Abman, S. H. (2008). Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. J Am Coll Cardiol 51: 161-169 [Abstract] [Full Text]  
• Otterdal, K., Andreassen, A. K., Yndestad, A., Oie, E., Sandberg, W. J., Dahl, C. P., Pedersen, T. M., Ueland, T., Gullestad, L., Brosstad, F. R., Aukrust, P., Damas, J. K. (2008). Raised LIGHT Levels in Pulmonary Arterial Hypertension: Potential Role in Thrombus Formation. Am. J. Respir. Crit. Care Med. 177: 202-207 [Abstract] [Full Text]  
• Obata, H., Sakai, Y., Ohnishi, S., Takeshita, S., Mori, H., Kodama, M., Kangawa, K., Aizawa, Y., Nagaya, N. (2008). Single Injection of a Sustained-release Prostacyclin Analog Improves Pulmonary Hypertension in Rats. Am. J. Respir. Crit. Care Med. 177: 195-201 [Abstract] [Full Text]  
• Pepke-Zaba, J., Gilbert, C., Collings, L., Brown, M. C. J. (2008). Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension. Chest 133: 183-189 [Abstract] [Full Text]  
• Sitbon, O., Lascoux-Combe, C., Delfraissy, J.-F., Yeni, P. G., Raffi, F., De Zuttere, D., Gressin, V., Clerson, P., Sereni, D., Simonneau, G. (2008). Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era. Am. J. Respir. Crit. Care Med. 177: 108-113 [Abstract] [Full Text]  
• Thenappan, T., Shah, S. J., Rich, S., Gomberg-Maitland, M. (2007). A USA-based registry for pulmonary arterial hypertension: 1982 2006. Eur Respir J 30: 1103-1110 [Abstract] [Full Text]  
• Ostergaard, L., Stankevicius, E., Andersen, M. R., Eskildsen-Helmond, Y., Ledet, T., Mulvany, M. J., Simonsen, U. (2007). Diminished NO release in chronic hypoxic human endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 293: H2894-H2903 [Abstract] [Full Text]  
• Price, L. C., Forrest, P., Sodhi, V., Adamson, D. L., Nelson-Piercy, C., Lucey, M., Howard, L. S. (2007). Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 99: 552-555 [Abstract] [Full Text]  
• McMurtry, M. S., Bonnet, S., Michelakis, E. D., Bonnet, S., Haromy, A., Archer, S. L. (2007). Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L933-L940 [Abstract] [Full Text]  
• Ito, T., Okada, T., Miyashita, H., Nomoto, T., Nonaka-Sarukawa, M., Uchibori, R., Maeda, Y., Urabe, M., Mizukami, H., Kume, A., Takahashi, M., Ikeda, U., Shimada, K., Ozawa, K. (2007). Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Circ. Res. 101: 734-741 [Abstract] [Full Text]  
• Huang, S., DeSantis, E. R. H. (2007). Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 64: 1922-1926 [Abstract] [Full Text]  
• Kuwano, K., Hashino, A., Asaki, T., Hamamoto, T., Yamada, T., Okubo, K., Kuwabara, K. (2007). 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. 322: 1181-1188 [Abstract] [Full Text]  
• Patel, H. H., Zhang, S., Murray, F., Suda, R. Y. S., Head, B. P., Yokoyama, U., Swaney, J. S., Niesman, I. R., Schermuly, R. T., Pullamsetti, S. S., Thistlethwaite, P. A., Miyanohara, A., Farquhar, M. G., Yuan, J. X.-J., Insel, P. A. (2007). Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J. 21: 2970-2979 [Abstract] [Full Text]  
• White, R. J., Meoli, D. F., Swarthout, R. F., Kallop, D. Y., Galaria, I. I., Harvey, J. L., Miller, C. M., Blaxall, B. C., Hall, C. M., Pierce, R. A., Cool, C. D., Taubman, M. B. (2007). Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L583-L590 [Abstract] [Full Text]  
• Smith, V., De Pauw, M., Brusselle, G., Van Praet, J., De Keyser, F. (2007). Re: Pulmonary arterial hypertension in connective tissue diseases. Rheumatology (Oxford) 46: 1510-1510 [Full Text]  
• Ito, T., Okada, T., Mimuro, J., Miyashita, H., Uchibori, R., Urabe, M., Mizukami, H., Kume, A., Takahashi, M., Ikeda, U., Sakata, Y., Shimada, K., Ozawa, K. (2007). Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats. Hypertension 50: 531-536 [Abstract] [Full Text]  
• Vermeersch, P., Buys, E., Pokreisz, P., Marsboom, G., Ichinose, F., Sips, P., Pellens, M., Gillijns, H., Swinnen, M., Graveline, A., Collen, D., Dewerchin, M., Brouckaert, P., Bloch, K. D., Janssens, S. (2007). Soluble Guanylate Cyclase-{alpha}1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia. Circulation 116: 936-943 [Abstract] [Full Text]  
• Humbert, M., Khaltaev, N., Bousquet, J., Souza, R. (2007). Pulmonary Hypertension: From an Orphan Disease to a Public Health Problem. Chest 132: 365-367 [Full Text]  
• Humbert, M. (2007). Dual endothelin receptor antagonism: setting standards in PAH. ERR 16: 13-18 [Abstract] [Full Text]  
• Humbert, M., Segal, E. S., Kiely, D. G., Carlsen, J., Schwierin, B., Hoeper, M. M. (2007). Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30: 338-344 [Abstract] [Full Text]  
• Yu, E. P K, Ostor, A. J K, Hall, F. C (2007). Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 66: 1122-1123 [Full Text]  
• Humbert, M. (2007). The burden of pulmonary hypertension. Eur Respir J 30: 1-2 [Full Text]  
• Zakrzewicz, A., Hecker, M., Marsh, L. M., Kwapiszewska, G., Nejman, B., Long, L., Seeger, W., Schermuly, R. T., Morrell, N. W., Morty, R. E., Eickelberg, O. (2007). Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension. Circulation 115: 2957-2968 [Abstract] [Full Text]  
• Etz, C. D., Welp, H. A., Tjan, T. D.T., Hoffmeier, A., Weigang, E., Scheld, H. H., Schmid, C. (2007). Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices. Ann. Thorac. Surg. 83: 1697-1705 [Abstract] [Full Text]  
• Perros, F., Dorfmuller, P., Souza, R., Durand-Gasselin, I., Godot, V., Capel, F., Adnot, S., Eddahibi, S., Mazmanian, M., Fadel, E., Herve, P., Simonneau, G., Emilie, D., Humbert, M. (2007). Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29: 937-943 [Abstract] [Full Text]  
• Remillard, C. V., Tigno, D. D., Platoshyn, O., Burg, E. D., Brevnova, E. E., Conger, D., Nicholson, A., Rana, B. K., Channick, R. N., Rubin, L. J., O'Connor, D. T., Yuan, J. X.-J. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 292: C1837-C1853 [Abstract] [Full Text]  
• Kerbaul, F., Brimioulle, S., Rondelet, B., Dewachter, C., Hubloue, I., Naeije, R. (2007). How Prostacyclin Improves Cardiac Output in Right Heart Failure in Conjunction with Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 175: 846-850 [Abstract] [Full Text]  
• Wipff, J., Kahan, A., Hachulla, E., Sibilia, J., Cabane, J., Meyer, O., Mouthon, L., Guillevin, L., Junien, C., Boileau, C., Allanore, Y. (2007). Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46: 622-625 [Abstract] [Full Text]  
• Oka, M., Homma, N., Taraseviciene-Stewart, L., Morris, K. G., Kraskauskas, D., Burns, N., Voelkel, N. F., McMurtry, I. F. (2007). Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. Circ. Res. 100: 923-929 [Abstract] [Full Text]  
• Jardim, C., Rochitte, C. E., Humbert, M., Rubenfeld, G., Jasinowodolinski, D., Carvalho, C. R. R., Souza, R. (2007). Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. Eur Respir J 29: 476-481 [Abstract] [Full Text]  
• Benedict, N. J. (2007). Sitaxsentan in the management of pulmonary arterial hypertension. Am J Health Syst Pharm 64: 363-368 [Abstract] [Full Text]  
• Montani, D., Souza, R., Binkert, C., Fischli, W., Simonneau, G., Clozel, M., Humbert, M. (2007). Endothelin-1/Endothelin-3 Ratio: A Potential Prognostic Factor of Pulmonary Arterial Hypertension. Chest 131: 101-108 [Abstract] [Full Text]  
• McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., Rubin, L. J. (2006). Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 174: 1257-1263 [Abstract] [Full Text]  
• Johnson, S. R., Mehta, S., Granton, J. T. (2006). Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review.. Eur Respir J 28: 999-1004 [Abstract] [Full Text]  
• Mereles, D., Ehlken, N., Kreuscher, S., Ghofrani, S., Hoeper, M. M., Halank, M., Meyer, F. J., Karger, G., Buss, J., Juenger, J., Holzapfel, N., Opitz, C., Winkler, J., Herth, F. F.J., Wilkens, H., Katus, H. A., Olschewski, H., Grunig, E. (2006). Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation 114: 1482-1489 [Abstract] [Full Text]  
• Said, S. I. (2006). Mediators and modulators of pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L547-L558 [Abstract] [Full Text]  
• Sticherling, M. (2006). The role of endothelin in connective tissue diseases. Rheumatology (Oxford) 45: iii8-iii10 [Abstract] [Full Text]  
• Kahler, C. M., Colleselli, D. (2006). Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology (Oxford) 45: iii11-iii13 [Abstract] [Full Text]  
• Zuckerbraun, B. S., Chin, B. Y., Wegiel, B., Billiar, T. R., Czsimadia, E., Rao, J., Shimoda, L., Ifedigbo, E., Kanno, S., Otterbein, L. E. (2006). Carbon monoxide reverses established pulmonary hypertension. J. Exp. Med. 203: 2109-2119 [Abstract] [Full Text]  
• Souza, R, Sitbon, O, Parent, F, Simonneau, G, Humbert, M (2006). Long term imatinib treatment in pulmonary arterial hypertension.. Thorax 61: 736-736 [Full Text]  
• Humbert, M., Simonneau, G., on behalf of the French Network on Pulmonary Arter, (2006). The Need for National Registries in Rare Diseases. Am. J. Respir. Crit. Care Med. 174: 228a-229 [Full Text]  
• Galie, N., Beghetti, M., Gatzoulis, M. A., Granton, J., Berger, R. M.F., Lauer, A., Chiossi, E., Landzberg, M., for the Bosentan Randomized Trial of Endothelin An, (2006). Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. Circulation 114: 48-54 [Abstract] [Full Text]  
• Sanchez, O., Sitbon, O., Jais, X., Simonneau, G., Humbert, M. (2006). Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.. Chest 130: 182-189 [Abstract] [Full Text]  
• Adriaenssens, T., Delcroix, M., Van Deyk, K., Budts, W. (2006). Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J 27: 1472-1477 [Abstract] [Full Text]  
• Lang, I., Gomez-Sanchez, M., Kneussl, M., Naeije, R., Escribano, P., Skoro-Sajer, N., Vachiery, J.-L. (2006). Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension. Chest 129: 1636-1643 [Abstract] [Full Text]  
• Lubomirov, L. T., Reimann, K., Metzler, D., Hasse, V., Stehle, R., Ito, M., Hartshorne, D. J., Gagov, H., Pfitzer, G., Schubert, R. (2006). Urocortin-Induced Decrease in Ca2+ Sensitivity of Contraction in Mouse Tail Arteries Is Attributable to cAMP-Dependent Dephosphorylation of MYPT1 and Activation of Myosin Light Chain Phosphatase. Circ. Res. 98: 1159-1167 [Abstract] [Full Text]  
• Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., Dromer, C., Pison, C., Reynaud-Gaubert, M., Haloun, A., Laurent, M., Hachulla, E., Simonneau, G. (2006). Pulmonary Arterial Hypertension in France: Results from a National Registry. Am. J. Respir. Crit. Care Med. 173: 1023-1030 [Abstract] [Full Text]  
• Al-Khaldi, A., Reitz, B. A., Zhu, H., Rosenthal, D. (2006). Heterotopic Heart Transplant Combined With Postoperative Sildenafil Use for the Treatment of Restrictive Cardiomyopathy. Ann. Thorac. Surg. 81: 1505-1507 [Abstract] [Full Text]  
• Provencher, S., Sitbon, O., Humbert, M., Cabrol, S., Jais, X., Simonneau, G. (2006). Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27: 589-595 [Abstract] [Full Text]  
• Rabiller, A., Jais, X., Hamid, A., Resten, A., Parent, F., Haque, R., Capron, F., Sitbon, O., Simonneau, G., Humbert, M. (2006). Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 27: 108-113 [Abstract] [Full Text]  
• Provencher, S., Chemla, D., Herve, P., Sitbon, O., Humbert, M., Simonneau, G. (2006). Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 27: 114-120 [Abstract] [Full Text]  
• Nunes, H, Humbert, M, Capron, F, Brauner, M, Sitbon, O, Battesti, J-P, Simonneau, G, Valeyre, D (2006). Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61: 68-74 [Abstract] [Full Text]  
• Provencher, S., Jais, X., Yaici, A., Sitbon, O., Humbert, M., Simonneau, G. (2005). Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture. Chest 128: 622S-628S [Abstract] [Full Text]  
• Provencher, S., Jais, X., Yaici, A., Sitbon, O., Humbert, M., Simonneau, G. (2005). Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture. Chest 128: 622S-628S [Abstract] [Full Text]  
• Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G., the Sildenafil Use in Pulmonary Arterial Hypertens, (2005). Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. NEJM 353: 2148-2157 [Abstract] [Full Text]  
• Montani, D., Achouh, L., Marcelin, A. G., Viard, J-P., Hermine, O., Canioni, D., Sitbon, O., Simonneau, G., Humbert, M. (2005). Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 26: 969-972 [Abstract] [Full Text]  
• DERCHI, G., FORNI, G. L. (2005). Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies: Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Ann. N. Y. Acad. Sci. 1054: 471-475 [Abstract] [Full Text]  
• Borlaug, B. A., Melenovsky, V., Marhin, T., Fitzgerald, P., Kass, D. A. (2005). Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans. Circulation 112: 2642-2649 [Abstract] [Full Text]  
• Baker, S. E, Hockman, R. H. (2005). Inhaled Iloprost in Pulmonary Arterial Hypertension. The Annals of Pharmacotherapy 39: 1265-1274 [Abstract] [Full Text]  
• Sitbon, O., Humbert, M., Jais, X., Ioos, V., Hamid, A. M., Provencher, S., Garcia, G., Parent, F., Herve, P., Simonneau, G. (2005). Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation 111: 3105-3111 [Abstract] [Full Text]  
• Barnes, P. J., Stockley, R. A. (2005). COPD: current therapeutic interventions and future approaches. Eur Respir J 25: 1084-1106 [Abstract] [Full Text]  
• Ford, K. (2005). Pulmonary artery hypertension: new drug treatment in children. EDUCATION AND PRACTICE 90: ep15-ep20 [Full Text]  
• McLaughin, V. V., Hoeper, M. M. (2005). Pulmonary Arterial Hypertension: The Race for the Most Effective Treatment. Am. J. Respir. Crit. Care Med. 171: 1199-1201 [Full Text]  
• Souza, R., Bogossian, H. B., Humbert, M., Jardim, C., Rabelo, R., Amato, M. B. P., Carvalho, C. R. R. (2005). N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 25: 509-513 [Abstract] [Full Text]  
• Humbert, M. (2005). Improving survival in pulmonary arterial hypertension. Eur Respir J 25: 218-220 [Full Text]  
• Huisman, A.-M., Vreugdenhil, S. A., van Paassen, H. C., Humbert, M., Sitbon, O., Simonneau, G. (2005). Treatment of Pulmonary Arterial Hypertension. NEJM 352: 308-309 [Full Text]  
• Naeije, R. (2005). Breathing more with weaker respiratory muscles in pulmonary arterial hypertension. Eur Respir J 25: 6-8 [Full Text]